Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report Article Swipe
Jaikumar Khatri
,
Ihab Tahboub
,
Khurram Anwar
,
Moh’d Masoudi
,
Vincent Graffeo
,
Muhammad Omer Jamil
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1177/23247096241231645
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1177/23247096241231645
Pfizer/BioNTech (BNT162b2) is a messenger RNA (mRNA) vaccine that is highly effective in preventing the most severe outcomes of COVID-19 infection. Nucleoside-modified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines induce effective stimulation of T follicular helper (TFH) cells, leading to a robust germinal center B cell response. Side effects from the BNT162b2 vaccination, including significant lymphadenopathy, have been reported previously. Here, we present a case of angioimmunoblastic lymphoma (AITL), a rare, peripheral T-cell lymphoma with RHOA-G17v-mutated gene developing in a patient following BNT162B2 vaccine with a plausible explanation. A 60-year-old Asian female received her first dose of Pfizer BNT162B2 mRNA vaccine in August 2021. Right after her vaccination, she developed right axillary lymphadenopathy. She received her second vaccine dose in September 2021. Thereafter, she developed lymph node (LN) enlargement in her neck and groin. She underwent left posterior cervical and left groin LN excisional biopsy in April 2022 due to persistent palpable lymphadenopathy. Biopsy results then demonstrated benign follicular hyperplasia. For progressive B symptoms, a right axillary LN biopsy was done, which demonstrated AITL, with molecular studies revealing mutation in TET-2, IDH-2, and RHOA-G17v genes. Progression of AITL following BNT162B2 mRNA vaccine is limited in literature. Our case demonstrates a plausible correlation between the diagnosis of AITL following mRNA vaccination due to the malignant transformation of the TFH cells in patients who have a predisposing mutation of RHOA-17v. Given the rarity of AITL and the heterogeneity of molecular findings, more studies are needed to establish such an association.
Related Topics
Concepts
Medicine
Angioimmunoblastic T-cell lymphoma
Vaccination
Lymphoma
Germinal center
Biopsy
Cervical lymphadenopathy
Pathology
Immunology
T cell
B cell
Antibody
Immune system
Disease
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1177/23247096241231645
- https://journals.sagepub.com/doi/pdf/10.1177/23247096241231645
- OA Status
- gold
- References
- 24
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4397033758
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4397033758Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1177/23247096241231645Digital Object Identifier
- Title
-
Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case ReportWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-01-01Full publication date if available
- Authors
-
Jaikumar Khatri, Ihab Tahboub, Khurram Anwar, Moh’d Masoudi, Vincent Graffeo, Muhammad Omer JamilList of authors in order
- Landing page
-
https://doi.org/10.1177/23247096241231645Publisher landing page
- PDF URL
-
https://journals.sagepub.com/doi/pdf/10.1177/23247096241231645Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://journals.sagepub.com/doi/pdf/10.1177/23247096241231645Direct OA link when available
- Concepts
-
Medicine, Angioimmunoblastic T-cell lymphoma, Vaccination, Lymphoma, Germinal center, Biopsy, Cervical lymphadenopathy, Pathology, Immunology, T cell, B cell, Antibody, Immune system, DiseaseTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
24Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4397033758 |
|---|---|
| doi | https://doi.org/10.1177/23247096241231645 |
| ids.doi | https://doi.org/10.1177/23247096241231645 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38761096 |
| ids.openalex | https://openalex.org/W4397033758 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D005260 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Female |
| mesh[2].qualifier_ui | Q000009 |
| mesh[2].descriptor_ui | D000090982 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | adverse effects |
| mesh[2].descriptor_name | BNT162 Vaccine |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008875 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Middle Aged |
| mesh[4].qualifier_ui | Q000235 |
| mesh[4].descriptor_ui | D020742 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | genetics |
| mesh[4].descriptor_name | rhoA GTP-Binding Protein |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D007119 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Immunoblastic Lymphadenopathy |
| mesh[6].qualifier_ui | Q000517 |
| mesh[6].descriptor_ui | D000086382 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | prevention & control |
| mesh[6].descriptor_name | COVID-19 |
| mesh[7].qualifier_ui | Q000009 |
| mesh[7].descriptor_ui | D000086663 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | adverse effects |
| mesh[7].descriptor_name | COVID-19 Vaccines |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D016411 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Lymphoma, T-Cell, Peripheral |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D000086402 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | SARS-CoV-2 |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D006801 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Humans |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D005260 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Female |
| mesh[12].qualifier_ui | Q000009 |
| mesh[12].descriptor_ui | D000090982 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | adverse effects |
| mesh[12].descriptor_name | BNT162 Vaccine |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D008875 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Middle Aged |
| mesh[14].qualifier_ui | Q000235 |
| mesh[14].descriptor_ui | D020742 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | genetics |
| mesh[14].descriptor_name | rhoA GTP-Binding Protein |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D007119 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Immunoblastic Lymphadenopathy |
| mesh[16].qualifier_ui | Q000517 |
| mesh[16].descriptor_ui | D000086382 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | prevention & control |
| mesh[16].descriptor_name | COVID-19 |
| mesh[17].qualifier_ui | Q000009 |
| mesh[17].descriptor_ui | D000086663 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | adverse effects |
| mesh[17].descriptor_name | COVID-19 Vaccines |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D016411 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Lymphoma, T-Cell, Peripheral |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000086402 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | SARS-CoV-2 |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006801 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Humans |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D005260 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Female |
| mesh[22].qualifier_ui | Q000009 |
| mesh[22].descriptor_ui | D000090982 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | adverse effects |
| mesh[22].descriptor_name | BNT162 Vaccine |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D008875 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Middle Aged |
| mesh[24].qualifier_ui | Q000235 |
| mesh[24].descriptor_ui | D020742 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | genetics |
| mesh[24].descriptor_name | rhoA GTP-Binding Protein |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D007119 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Immunoblastic Lymphadenopathy |
| mesh[26].qualifier_ui | Q000517 |
| mesh[26].descriptor_ui | D000086382 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | prevention & control |
| mesh[26].descriptor_name | COVID-19 |
| mesh[27].qualifier_ui | Q000009 |
| mesh[27].descriptor_ui | D000086663 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | adverse effects |
| mesh[27].descriptor_name | COVID-19 Vaccines |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D016411 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Lymphoma, T-Cell, Peripheral |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D000086402 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | SARS-CoV-2 |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D006801 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Humans |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D005260 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Female |
| mesh[32].qualifier_ui | Q000009 |
| mesh[32].descriptor_ui | D000090982 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | adverse effects |
| mesh[32].descriptor_name | BNT162 Vaccine |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D008875 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Middle Aged |
| mesh[34].qualifier_ui | Q000235 |
| mesh[34].descriptor_ui | D020742 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | genetics |
| mesh[34].descriptor_name | rhoA GTP-Binding Protein |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D007119 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Immunoblastic Lymphadenopathy |
| mesh[36].qualifier_ui | Q000517 |
| mesh[36].descriptor_ui | D000086382 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | prevention & control |
| mesh[36].descriptor_name | COVID-19 |
| mesh[37].qualifier_ui | Q000009 |
| mesh[37].descriptor_ui | D000086663 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | adverse effects |
| mesh[37].descriptor_name | COVID-19 Vaccines |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D016411 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Lymphoma, T-Cell, Peripheral |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D000086402 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | SARS-CoV-2 |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D006801 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Humans |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D005260 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Female |
| mesh[42].qualifier_ui | Q000009 |
| mesh[42].descriptor_ui | D000090982 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | adverse effects |
| mesh[42].descriptor_name | BNT162 Vaccine |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D008875 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Middle Aged |
| mesh[44].qualifier_ui | Q000235 |
| mesh[44].descriptor_ui | D020742 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | genetics |
| mesh[44].descriptor_name | rhoA GTP-Binding Protein |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D007119 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Immunoblastic Lymphadenopathy |
| mesh[46].qualifier_ui | Q000517 |
| mesh[46].descriptor_ui | D000086382 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | prevention & control |
| mesh[46].descriptor_name | COVID-19 |
| mesh[47].qualifier_ui | Q000009 |
| mesh[47].descriptor_ui | D000086663 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | adverse effects |
| mesh[47].descriptor_name | COVID-19 Vaccines |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D016411 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Lymphoma, T-Cell, Peripheral |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D000086402 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | SARS-CoV-2 |
| type | article |
| title | Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report |
| biblio.issue | |
| biblio.volume | 12 |
| biblio.last_page | 23247096241231645 |
| biblio.first_page | 23247096241231645 |
| topics[0].id | https://openalex.org/T13314 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9961000084877014 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Lymphadenopathy Diagnosis and Analysis |
| topics[1].id | https://openalex.org/T10185 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9954000115394592 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Lymphoma Diagnosis and Treatment |
| topics[2].id | https://openalex.org/T11491 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9904999732971191 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | CAR-T cell therapy research |
| is_xpac | False |
| apc_list.value | 750 |
| apc_list.currency | USD |
| apc_list.value_usd | 750 |
| apc_paid.value | 750 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 750 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.827599287033081 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2776365654 |
| concepts[1].level | 4 |
| concepts[1].score | 0.6012378334999084 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q4763257 |
| concepts[1].display_name | Angioimmunoblastic T-cell lymphoma |
| concepts[2].id | https://openalex.org/C22070199 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5313813090324402 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q192995 |
| concepts[2].display_name | Vaccination |
| concepts[3].id | https://openalex.org/C2779338263 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5221672058105469 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[3].display_name | Lymphoma |
| concepts[4].id | https://openalex.org/C96926380 |
| concepts[4].level | 4 |
| concepts[4].score | 0.47685039043426514 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1737968 |
| concepts[4].display_name | Germinal center |
| concepts[5].id | https://openalex.org/C2775934546 |
| concepts[5].level | 2 |
| concepts[5].score | 0.45448753237724304 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q179991 |
| concepts[5].display_name | Biopsy |
| concepts[6].id | https://openalex.org/C2779655305 |
| concepts[6].level | 3 |
| concepts[6].score | 0.43021607398986816 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q5065339 |
| concepts[6].display_name | Cervical lymphadenopathy |
| concepts[7].id | https://openalex.org/C142724271 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3321593403816223 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[7].display_name | Pathology |
| concepts[8].id | https://openalex.org/C203014093 |
| concepts[8].level | 1 |
| concepts[8].score | 0.26146018505096436 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[8].display_name | Immunology |
| concepts[9].id | https://openalex.org/C2776090121 |
| concepts[9].level | 3 |
| concepts[9].score | 0.23408576846122742 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q193529 |
| concepts[9].display_name | T cell |
| concepts[10].id | https://openalex.org/C2778453870 |
| concepts[10].level | 3 |
| concepts[10].score | 0.17035320401191711 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q188930 |
| concepts[10].display_name | B cell |
| concepts[11].id | https://openalex.org/C159654299 |
| concepts[11].level | 2 |
| concepts[11].score | 0.14672210812568665 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[11].display_name | Antibody |
| concepts[12].id | https://openalex.org/C8891405 |
| concepts[12].level | 2 |
| concepts[12].score | 0.10379979014396667 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[12].display_name | Immune system |
| concepts[13].id | https://openalex.org/C2779134260 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[13].display_name | Disease |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.827599287033081 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/angioimmunoblastic-t-cell-lymphoma |
| keywords[1].score | 0.6012378334999084 |
| keywords[1].display_name | Angioimmunoblastic T-cell lymphoma |
| keywords[2].id | https://openalex.org/keywords/vaccination |
| keywords[2].score | 0.5313813090324402 |
| keywords[2].display_name | Vaccination |
| keywords[3].id | https://openalex.org/keywords/lymphoma |
| keywords[3].score | 0.5221672058105469 |
| keywords[3].display_name | Lymphoma |
| keywords[4].id | https://openalex.org/keywords/germinal-center |
| keywords[4].score | 0.47685039043426514 |
| keywords[4].display_name | Germinal center |
| keywords[5].id | https://openalex.org/keywords/biopsy |
| keywords[5].score | 0.45448753237724304 |
| keywords[5].display_name | Biopsy |
| keywords[6].id | https://openalex.org/keywords/cervical-lymphadenopathy |
| keywords[6].score | 0.43021607398986816 |
| keywords[6].display_name | Cervical lymphadenopathy |
| keywords[7].id | https://openalex.org/keywords/pathology |
| keywords[7].score | 0.3321593403816223 |
| keywords[7].display_name | Pathology |
| keywords[8].id | https://openalex.org/keywords/immunology |
| keywords[8].score | 0.26146018505096436 |
| keywords[8].display_name | Immunology |
| keywords[9].id | https://openalex.org/keywords/t-cell |
| keywords[9].score | 0.23408576846122742 |
| keywords[9].display_name | T cell |
| keywords[10].id | https://openalex.org/keywords/b-cell |
| keywords[10].score | 0.17035320401191711 |
| keywords[10].display_name | B cell |
| keywords[11].id | https://openalex.org/keywords/antibody |
| keywords[11].score | 0.14672210812568665 |
| keywords[11].display_name | Antibody |
| keywords[12].id | https://openalex.org/keywords/immune-system |
| keywords[12].score | 0.10379979014396667 |
| keywords[12].display_name | Immune system |
| language | en |
| locations[0].id | doi:10.1177/23247096241231645 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764765636 |
| locations[0].source.issn | 2324-7096 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2324-7096 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Journal of Investigative Medicine High Impact Case Reports |
| locations[0].source.host_organization | https://openalex.org/P4310320017 |
| locations[0].source.host_organization_name | SAGE Publishing |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320017 |
| locations[0].source.host_organization_lineage_names | SAGE Publishing |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://journals.sagepub.com/doi/pdf/10.1177/23247096241231645 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Investigative Medicine High Impact Case Reports |
| locations[0].landing_page_url | https://doi.org/10.1177/23247096241231645 |
| locations[1].id | pmid:38761096 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of investigative medicine high impact case reports |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38761096 |
| locations[2].id | pmh:oai:doaj.org/article:c97c2da5eb9e4cf594fdb8e1965afa6a |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Journal of Investigative Medicine High Impact Case Reports, Vol 12 (2024) |
| locations[2].landing_page_url | https://doaj.org/article/c97c2da5eb9e4cf594fdb8e1965afa6a |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:11102676 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | J Investig Med High Impact Case Rep |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11102676 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5023705523 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5253-8775 |
| authorships[0].author.display_name | Jaikumar Khatri |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I88694374 |
| authorships[0].affiliations[0].raw_affiliation_string | Marshall University, Huntington, WV, USA |
| authorships[0].institutions[0].id | https://openalex.org/I88694374 |
| authorships[0].institutions[0].ror | https://ror.org/02erqft81 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I88694374 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Marshall University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jai Kumar Khatri |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Marshall University, Huntington, WV, USA |
| authorships[1].author.id | https://openalex.org/A5087206597 |
| authorships[1].author.orcid | https://orcid.org/0009-0001-5015-2905 |
| authorships[1].author.display_name | Ihab Tahboub |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I88694374 |
| authorships[1].affiliations[0].raw_affiliation_string | Marshall University, Huntington, WV, USA |
| authorships[1].institutions[0].id | https://openalex.org/I88694374 |
| authorships[1].institutions[0].ror | https://ror.org/02erqft81 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I88694374 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Marshall University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Ihab Tahboub |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Marshall University, Huntington, WV, USA |
| authorships[2].author.id | https://openalex.org/A5070829505 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Khurram Anwar |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I88694374 |
| authorships[2].affiliations[0].raw_affiliation_string | Marshall University, Huntington, WV, USA |
| authorships[2].institutions[0].id | https://openalex.org/I88694374 |
| authorships[2].institutions[0].ror | https://ror.org/02erqft81 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I88694374 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Marshall University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Khurram Anwar |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Marshall University, Huntington, WV, USA |
| authorships[3].author.id | https://openalex.org/A5006969348 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Moh’d Masoudi |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I88694374 |
| authorships[3].affiliations[0].raw_affiliation_string | Marshall University, Huntington, WV, USA |
| authorships[3].institutions[0].id | https://openalex.org/I88694374 |
| authorships[3].institutions[0].ror | https://ror.org/02erqft81 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I88694374 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Marshall University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Moh’d Masoudi |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Marshall University, Huntington, WV, USA |
| authorships[4].author.id | https://openalex.org/A5051915104 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-5659-5432 |
| authorships[4].author.display_name | Vincent Graffeo |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I88694374 |
| authorships[4].affiliations[0].raw_affiliation_string | Marshall University, Huntington, WV, USA |
| authorships[4].institutions[0].id | https://openalex.org/I88694374 |
| authorships[4].institutions[0].ror | https://ror.org/02erqft81 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I88694374 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Marshall University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Vincent Graffeo |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Marshall University, Huntington, WV, USA |
| authorships[5].author.id | https://openalex.org/A5068287599 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Muhammad Omer Jamil |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I88694374 |
| authorships[5].affiliations[0].raw_affiliation_string | Marshall University, Huntington, WV, USA |
| authorships[5].institutions[0].id | https://openalex.org/I88694374 |
| authorships[5].institutions[0].ror | https://ror.org/02erqft81 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I88694374 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Marshall University |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Muhammad Omer Jamil |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Marshall University, Huntington, WV, USA |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://journals.sagepub.com/doi/pdf/10.1177/23247096241231645 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T13314 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9961000084877014 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Lymphadenopathy Diagnosis and Analysis |
| related_works | https://openalex.org/W2806435074, https://openalex.org/W2150431303, https://openalex.org/W3139387050, https://openalex.org/W3009549504, https://openalex.org/W2106274611, https://openalex.org/W2050908246, https://openalex.org/W2171120486, https://openalex.org/W4242155622, https://openalex.org/W2192919106, https://openalex.org/W4200342049 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1177/23247096241231645 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764765636 |
| best_oa_location.source.issn | 2324-7096 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2324-7096 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Journal of Investigative Medicine High Impact Case Reports |
| best_oa_location.source.host_organization | https://openalex.org/P4310320017 |
| best_oa_location.source.host_organization_name | SAGE Publishing |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320017 |
| best_oa_location.source.host_organization_lineage_names | SAGE Publishing |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://journals.sagepub.com/doi/pdf/10.1177/23247096241231645 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Investigative Medicine High Impact Case Reports |
| best_oa_location.landing_page_url | https://doi.org/10.1177/23247096241231645 |
| primary_location.id | doi:10.1177/23247096241231645 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764765636 |
| primary_location.source.issn | 2324-7096 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2324-7096 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Journal of Investigative Medicine High Impact Case Reports |
| primary_location.source.host_organization | https://openalex.org/P4310320017 |
| primary_location.source.host_organization_name | SAGE Publishing |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320017 |
| primary_location.source.host_organization_lineage_names | SAGE Publishing |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://journals.sagepub.com/doi/pdf/10.1177/23247096241231645 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Investigative Medicine High Impact Case Reports |
| primary_location.landing_page_url | https://doi.org/10.1177/23247096241231645 |
| publication_date | 2024-01-01 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W3177181935, https://openalex.org/W2802953285, https://openalex.org/W1991311051, https://openalex.org/W1995204178, https://openalex.org/W2065338955, https://openalex.org/W3113734454, https://openalex.org/W3111255098, https://openalex.org/W3215008874, https://openalex.org/W2894112953, https://openalex.org/W2146604395, https://openalex.org/W3082694457, https://openalex.org/W3121716160, https://openalex.org/W3187857637, https://openalex.org/W3131137233, https://openalex.org/W3162432175, https://openalex.org/W3131019737, https://openalex.org/W3009821158, https://openalex.org/W2137446997, https://openalex.org/W2146146853, https://openalex.org/W2069271377, https://openalex.org/W2767840526, https://openalex.org/W2786374981, https://openalex.org/W4210820143, https://openalex.org/W4205483821 |
| referenced_works_count | 24 |
| abstract_inverted_index.2 | 27 |
| abstract_inverted_index.A | 90 |
| abstract_inverted_index.B | 46, 164 |
| abstract_inverted_index.T | 35 |
| abstract_inverted_index.a | 3, 42, 65, 71, 81, 87, 166, 201, 225 |
| abstract_inverted_index.LN | 144, 169 |
| abstract_inverted_index.an | 248 |
| abstract_inverted_index.in | 12, 80, 103, 121, 131, 147, 181, 196, 221 |
| abstract_inverted_index.is | 2, 9, 194 |
| abstract_inverted_index.of | 18, 34, 67, 98, 188, 207, 217, 228, 233, 238 |
| abstract_inverted_index.to | 41, 151, 213, 245 |
| abstract_inverted_index.we | 63 |
| abstract_inverted_index.For | 162 |
| abstract_inverted_index.Our | 198 |
| abstract_inverted_index.RNA | 5 |
| abstract_inverted_index.She | 115, 136 |
| abstract_inverted_index.TFH | 219 |
| abstract_inverted_index.and | 134, 141, 184, 235 |
| abstract_inverted_index.are | 243 |
| abstract_inverted_index.due | 150, 212 |
| abstract_inverted_index.her | 95, 108, 117, 132 |
| abstract_inverted_index.she | 110, 125 |
| abstract_inverted_index.the | 14, 52, 205, 214, 218, 231, 236 |
| abstract_inverted_index.was | 171 |
| abstract_inverted_index.who | 223 |
| abstract_inverted_index.(LN) | 129 |
| abstract_inverted_index.2022 | 149 |
| abstract_inverted_index.AITL | 189, 208, 234 |
| abstract_inverted_index.Side | 49 |
| abstract_inverted_index.been | 59 |
| abstract_inverted_index.case | 66, 199 |
| abstract_inverted_index.cell | 47 |
| abstract_inverted_index.dose | 97, 120 |
| abstract_inverted_index.from | 51 |
| abstract_inverted_index.gene | 78 |
| abstract_inverted_index.have | 58, 224 |
| abstract_inverted_index.left | 138, 142 |
| abstract_inverted_index.mRNA | 29, 101, 192, 210 |
| abstract_inverted_index.more | 241 |
| abstract_inverted_index.most | 15 |
| abstract_inverted_index.neck | 133 |
| abstract_inverted_index.node | 128 |
| abstract_inverted_index.such | 247 |
| abstract_inverted_index.that | 8 |
| abstract_inverted_index.then | 157 |
| abstract_inverted_index.with | 76, 86, 176 |
| abstract_inverted_index.(TFH) | 38 |
| abstract_inverted_index.2021. | 105, 123 |
| abstract_inverted_index.AITL, | 175 |
| abstract_inverted_index.April | 148 |
| abstract_inverted_index.Asian | 92 |
| abstract_inverted_index.Given | 230 |
| abstract_inverted_index.Here, | 62 |
| abstract_inverted_index.Right | 106 |
| abstract_inverted_index.acute | 23 |
| abstract_inverted_index.after | 107 |
| abstract_inverted_index.cells | 220 |
| abstract_inverted_index.done, | 172 |
| abstract_inverted_index.first | 96 |
| abstract_inverted_index.groin | 143 |
| abstract_inverted_index.lymph | 127 |
| abstract_inverted_index.rare, | 72 |
| abstract_inverted_index.right | 112, 167 |
| abstract_inverted_index.which | 173 |
| abstract_inverted_index.(mRNA) | 6 |
| abstract_inverted_index.August | 104 |
| abstract_inverted_index.Biopsy | 155 |
| abstract_inverted_index.IDH-2, | 183 |
| abstract_inverted_index.Pfizer | 99 |
| abstract_inverted_index.T-cell | 74 |
| abstract_inverted_index.TET-2, | 182 |
| abstract_inverted_index.benign | 159 |
| abstract_inverted_index.biopsy | 146, 170 |
| abstract_inverted_index.cells, | 39 |
| abstract_inverted_index.center | 45 |
| abstract_inverted_index.female | 93 |
| abstract_inverted_index.genes. | 186 |
| abstract_inverted_index.groin. | 135 |
| abstract_inverted_index.helper | 37 |
| abstract_inverted_index.highly | 10 |
| abstract_inverted_index.induce | 31 |
| abstract_inverted_index.needed | 244 |
| abstract_inverted_index.rarity | 232 |
| abstract_inverted_index.robust | 43 |
| abstract_inverted_index.second | 118 |
| abstract_inverted_index.severe | 16, 22 |
| abstract_inverted_index.(AITL), | 70 |
| abstract_inverted_index.between | 204 |
| abstract_inverted_index.effects | 50 |
| abstract_inverted_index.leading | 40 |
| abstract_inverted_index.limited | 195 |
| abstract_inverted_index.patient | 82 |
| abstract_inverted_index.present | 64 |
| abstract_inverted_index.results | 156 |
| abstract_inverted_index.studies | 178, 242 |
| abstract_inverted_index.vaccine | 7, 85, 102, 119, 193 |
| abstract_inverted_index.BNT162B2 | 84, 100, 191 |
| abstract_inverted_index.BNT162b2 | 53 |
| abstract_inverted_index.COVID-19 | 19 |
| abstract_inverted_index.axillary | 113, 168 |
| abstract_inverted_index.cervical | 140 |
| abstract_inverted_index.germinal | 44 |
| abstract_inverted_index.lymphoma | 69, 75 |
| abstract_inverted_index.mutation | 180, 227 |
| abstract_inverted_index.outcomes | 17 |
| abstract_inverted_index.palpable | 153 |
| abstract_inverted_index.patients | 222 |
| abstract_inverted_index.received | 94, 116 |
| abstract_inverted_index.reported | 60 |
| abstract_inverted_index.syndrome | 25 |
| abstract_inverted_index.vaccines | 30 |
| abstract_inverted_index.RHOA-17v. | 229 |
| abstract_inverted_index.RHOA-G17v | 185 |
| abstract_inverted_index.September | 122 |
| abstract_inverted_index.developed | 111, 126 |
| abstract_inverted_index.diagnosis | 206 |
| abstract_inverted_index.effective | 11, 32 |
| abstract_inverted_index.establish | 246 |
| abstract_inverted_index.findings, | 240 |
| abstract_inverted_index.following | 83, 190, 209 |
| abstract_inverted_index.including | 55 |
| abstract_inverted_index.malignant | 215 |
| abstract_inverted_index.messenger | 4 |
| abstract_inverted_index.molecular | 177, 239 |
| abstract_inverted_index.plausible | 88, 202 |
| abstract_inverted_index.posterior | 139 |
| abstract_inverted_index.response. | 48 |
| abstract_inverted_index.revealing | 179 |
| abstract_inverted_index.symptoms, | 165 |
| abstract_inverted_index.underwent | 137 |
| abstract_inverted_index.(BNT162b2) | 1 |
| abstract_inverted_index.developing | 79 |
| abstract_inverted_index.excisional | 145 |
| abstract_inverted_index.follicular | 36, 160 |
| abstract_inverted_index.infection. | 20 |
| abstract_inverted_index.peripheral | 73 |
| abstract_inverted_index.persistent | 152 |
| abstract_inverted_index.preventing | 13 |
| abstract_inverted_index.60-year-old | 91 |
| abstract_inverted_index.Progression | 187 |
| abstract_inverted_index.Thereafter, | 124 |
| abstract_inverted_index.coronavirus | 26 |
| abstract_inverted_index.correlation | 203 |
| abstract_inverted_index.enlargement | 130 |
| abstract_inverted_index.literature. | 197 |
| abstract_inverted_index.previously. | 61 |
| abstract_inverted_index.progressive | 163 |
| abstract_inverted_index.respiratory | 24 |
| abstract_inverted_index.significant | 56 |
| abstract_inverted_index.stimulation | 33 |
| abstract_inverted_index.vaccination | 211 |
| abstract_inverted_index.(SARS-CoV-2) | 28 |
| abstract_inverted_index.association. | 249 |
| abstract_inverted_index.demonstrated | 158, 174 |
| abstract_inverted_index.demonstrates | 200 |
| abstract_inverted_index.explanation. | 89 |
| abstract_inverted_index.hyperplasia. | 161 |
| abstract_inverted_index.predisposing | 226 |
| abstract_inverted_index.vaccination, | 54, 109 |
| abstract_inverted_index.heterogeneity | 237 |
| abstract_inverted_index.transformation | 216 |
| abstract_inverted_index.Pfizer/BioNTech | 0 |
| abstract_inverted_index.lymphadenopathy, | 57 |
| abstract_inverted_index.lymphadenopathy. | 114, 154 |
| abstract_inverted_index.RHOA-G17v-mutated | 77 |
| abstract_inverted_index.angioimmunoblastic | 68 |
| abstract_inverted_index.Nucleoside-modified | 21 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5023705523 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| corresponding_institution_ids | https://openalex.org/I88694374 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.15797409 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |